RainbowUnicorn
Researcher
Posts: 103
Sentiment: Way Too Long
Member is Online
|
Post by RainbowUnicorn on Mar 3, 2022 1:00:15 GMT -5
|
|
|
|
Post by nylefty on Mar 3, 2022 3:12:27 GMT -5
|
|
|
|
Post by hellodolly on Mar 3, 2022 8:22:00 GMT -5
Solution v Inhalation. This does not impact the distribution of MNKD's inhalation powder, except TAM correct? Some may prefer their liquid solution...others the powder? |
|
|
|
Post by uvula on Mar 3, 2022 8:27:23 GMT -5
Is my interpretation correct: PH can be treated with injected or inhaled trespostinal but pulmonary hypertension associated with interstitial lung disease (PH-ILD) can only be treated with inhaled trespostinal? (Once again, my interpretation. This could be wrong.)
If this is not correct then why is there currently no treatment option for pd-ild in some countries?
|
|
|
|
Post by mango on Mar 4, 2022 13:49:01 GMT -5
Is my interpretation correct: PH can be treated with injected or inhaled trespostinal but pulmonary hypertension associated with interstitial lung disease (PH-ILD) can only be treated with inhaled trespostinal? (Once again, my interpretation. This could be wrong.) If this is not correct then why is there currently no treatment option for pd-ild in some countries? There’s currently no FDA approved therapy for PH-ILD. Tyvaso and Tyvaso DPI would be the first and only FDA approved drug for PH-ILD and have will zero competition along with exclusivity (same applies to PH-COPD when they get that indication). |
|
